作者: Yoko Shimoda , Joji Yui , Masayuki Fujinaga , Lin Xie , Katsushi Kumata
DOI: 10.1016/J.BMCL.2014.05.045
关键词:
摘要: CEP-32496 is a novel, orally active serine/threonine-protein kinase B-raf (BRAF) (V600E) inhibitor that being investigated in clinical trials for the treatment of some cancers patients. In this study, we developed [(11)C-carbonyl]CEP-32496 as novel positron emission tomography (PET) probe to study its biodistribution whole bodies mice. [(11)C]CEP-32496 was synthesized by reaction 5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-amine hydrochloride (1·HCl) with [(11)C]phosgene, followed 3-(6,7-dimethoxyquinozolin-4-yloxy)aniline (2). Small-animal PET studies indicated radioactivity levels (AUC0-90 min, SUV×min) accumulated brains P-gp/BCRP knockout mice at 8-fold higher rate than wild-type